Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: Analysis of 501 consecutively treated patients

Annals of Surgery

Volumn 262, Issue 3, 2015, Pages 536-543

  Agopian, Vatche G ^a   Morshedi, Maud M ^a   McWilliams, Justin ^a   Harlander Locke, Michael P ^a   Markovic, Daniela ^a   Zarrinpar, Ali ^a   Kaldas, Fady M ^a   Farmer, Douglas G ^a   Yersiz, Hasan ^a   Hiatt, Jonathan R ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complete pathologic response; Hepatocellular carcinoma; Liver transplantation; Locoregional therapy; Posttransplant recurrence

Indexed keywords

ALPHA FETOPROTEIN; CHOLESTEROL;

ADULT; AGED; ALCOHOL LIVER DISEASE; CANCER RECURRENCE; CANCER THERAPY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; COMPLETE PATHOLOGIC RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOCOREGIONAL THERAPY; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; ADJUVANT THERAPY; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; EVALUATION STUDY; FACTUAL DATABASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; NONPARAMETRIC TEST; PREDICTIVE VALUE; PREOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942540535     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001384     Document Type: Conference Paper

References (41)

1. Mazzaferro V, Regalia E, Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N England J Med. 1996; 334:693-699.
2. Wiesner R, Edwards E, Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124:91-96.
3. Brown RS, Rush SH, Rosen H.R., et al. Liver and intestine transplantation. Am J Transplant. 2004; 4:81-92.
4. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008; 134:1342-1351.
5. Washburn K, Edwards E, Harper A., et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant. 2010; 10:1643-1648.
6. Massie AB, Caffo B, Gentry S.E., et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant. 2011; 11:2362-2371.
7. Kim WR, Stock PG, Smith J.M., et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant. 2013; 13:73-102.
8. Singal AK, Guturu P, Hmoud B., et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013; 95:755-760.
9. Agopian VG, Petrowsky H, Kaldas F.M., et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg. 2013; 258:409-421.
10. Heimbach JK, Hirose R, Stock P.G., et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015; 61:1643-1650.
11. Cucchetti A, Cescon M, Bertuzzo V., et al. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? Am J Transplant. 2011; 11:1696-1704.
12. Merani S, Majno P, Kneteman N.M., et al. The impact of waiting list alphafetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011; 55:814-819.
13. Agopian VG, Harlander-Locke M, Zarrinpar A., et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015; 220:416-427.
14. Golfieri R, Cappelli A, Cucchetti A., et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011; 53:1580-1589.
15. Kwan SW, Fidelman N, Ma E., et al. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012; 18:727-736.
16. Lu DS, Yu NC, Raman S.S., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005; 41:1130-1137.
17. Mazzaferro V, Battiston C, Perrone S., et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004; 240:900-909.
18. Pompili M, Mirante VG, Rondinara G, et al Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005; 11:1117-1126.
19. Alba E, Valls C, Dominguez J., et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol. 2008; 190:1341-1348.
20. Majno PE, Adam R, Bismuth H., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997; 226:688-701; discussion 701-703
21. Millonig G, Graziadei IW, Freund M.C., et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007; 13:272-279.
22. Tsochatzis E, Garcovich M, Marelli L., et al. Transarterial embolization as neoadjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013; 33:944-949.
23. Freeman RB J.r., Steffick DE, Guidinger M.K., et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant. 2008; 8: 958-976.
24. Lesurtel M, Mullhaupt B, Pestalozzi B.C., et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant. 2006; 6:2644-2650.
25. Terzi E, Ray Kim W, Sanchez W, et al Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015; 21:248-257.
26. Yao FY, Ferrell L, Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33:1394-1403.
27. Pompili M, Francica G, Ponziani F.R., et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013; 19:7515-7530.
28. Cucchetti A, Cescon M, Bigonzi E., et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl. 2011; 17:1344-1354.
29. Allard MA, Sebagh M, Ruiz A., et al. Does pathological response for hepatocellular carcinoma in patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol. 2015 January 31. [Epub ahead of print].
30. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011; 11: 2031-2035.
31. Ashoori N, Bamberg F, Paprottka P., et al. Multimodality treatment for earlystage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion. 2012; 86:338-348.
32. Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30:52-60.
33. Mehta N, Dodge JL, Goel A, et al Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013; 19:1343-1353.
34. Otto G, Herber S, Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006; 12:1260-1267.
35. Vitale A, D'Amico F, Frigo AC, et al Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg. Oncol. 2010; 17:2290-2302.
36. Lai Q, Avolio AW, Graziadei I, et al Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013; 19:1108-1118.
37. Halazun KJ, Patzer RE, Rana A.A., et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014; 60: 1957-1962.
38. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008; 248:617-625.
39. Yao FY, Kerlan RK, Jr, Hirose R, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48:819-827.
40. Roberts JP, Venook A, Kerlan R., et al. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl. 2010; 16:925-929.
41. Samoylova ML, Dodge JL, Yao F.Y., et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014; 20:937-944.